($LTRN) Does It Make Sense for Lantern to Announce withZeta Before BIO2026?

Interesting timing question regarding withZeta. Lantern's CEO, Panna Sharma, is scheduled to participate in a BIO2026 executive roundtable on June 23 focused on AI-driven drug development, biotech innovation, and the future of life sciences. Given that management has repeatedly highlighted withZeta, discussed commercialization plans, and suggested it could become a meaningful value driver, I can't help but wonder: Would management prefer to provide a withZeta update before such an event? I'm not